Is kidney injury from Selpercatinib reversible?

Reversible. Typical onset: Hypertension within the first weeks to months; creatinine changes early..

How should kidney function be monitored during Selpercatinib therapy?

Blood pressure at baseline, after 1 week, at least monthly, and as clinically indicated; Serum creatinine periodically; cystatin C-based eGFR if a true GFR change is suspected; ECG/QTc and liver enzymes per label.

How can kidney injury from Selpercatinib be prevented?

Optimize antihypertensives before/during therapy

Who is at higher risk of kidney injury from Selpercatinib?

Pre-existing hypertension; Cardiovascular disease; Concurrent nephrotoxins or QT-prolonging drugs.

Back to explorer

Printable monograph

RET inhibitor

Selpercatinib

Retevmo · Selp

RET inhibitor · approved 2020 · 11 citations

Up to date· through 2026

Fairly sourced5/9 · 5 signals

Met: 11 citations
Not met: 12+ references
Not met: Accrued over 10+ years (span: 6y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2026
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A selective RET inhibitor whose cardiometabolic signature includes hypertension and creatinine rise.

ModerateRET inhibitor

RET fusion-positive NSCLCRET fusion-positive thyroid cancerRET-mutant medullary thyroid cancer

§01

Signature kidney injury

Signature lesion

Hypertension

Representative grade ≥3 incidence19.7%

Hypertension is among the most common adverse events in LIBRETTO-001 (a frequent grade >=3 event), and a reversible serum-creatinine increase is also recognized. A single-center hereditary-MTC series found hypertension in ~26% on selective RET inhibitors. Reported rate: grade >=3 hypertension in 19.7% — 837 patients with RET-activated advanced/metastatic solid tumors receiving selpercatinib monotherapy (20 mg QD to 240… (Raez 2024, PMID 39471424).Source: Raez et al., Oncologist 2024

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Hypertension within the first weeks to months; creatinine changes early.

Distilled from: “Hypertension within the first weeks to months; creatinine changes early.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Hypertension#1 · Signature14%PMID 32846060 (opens PubMed in a new tab)
Grade >=3 hypertension in 14% of RET fusion-positive NSCLC and 21% of RET-mutant medullary thyroid cancer (LIBRETTO-001); the most common grade >=3 adverse event
Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Pseudo-AKIRarequalitative — no citable incidence
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Glomerular Injury / ProteinuriaRarequalitative — no citable incidence
A single biopsy-worked-up, dose-responsive nephropathy case - distinct from the transporter creatinine artifact.
SIADH / HyponatremiaRarequalitative — no citable incidence
Two drug-specific reports: SIADH with positive dechallenge, and tubular damage with symptomatic hyponatremia.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

19.7%grade ≥3 incidence

SeverityModerate

ReversibilityReversible

Evidence11 citations

Nephron map

GlomerulusFiltration barrier (podocytes + endothelium)

Vasculature / EndotheliumGlomerular & peritubular capillaries

Proximal Tubule

Distal Tubule / Collecting Duct

Hypertension

Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.

§03

Kidney injury

Deep divePseudo-AKI: the creatinine rises and the kidney is fineCreatinine does not only filter — a fifth of it is pushed into the urine by tubular transporters, and a drug that blocks those transporters raises the number without touching the glomerulus, producing a rise that looks like acute kidney injury on every axis except the one that matters.

Mechanism of kidney injury

Hypertension is an on/near-target vascular effect of RET-pathway inhibition (with endothelial/nitric-oxide and vascular-tone contributions shared by many kinase inhibitors). The creatinine rise is thought to reflect, at least in part, inhibition of tubular creatinine secretion (pseudo-AKI) rather than true GFR decline, although hemodynamic (hypertension-mediated) effects may contribute.

Clinical presentation

New or worsened hypertension; mild reversible creatinine elevation without active sediment, with a stable cystatin C-based eGFR in the transporter-mediated cases. QT prolongation and transaminitis are other class effects to monitor.

Management

Standard antihypertensive therapy (and lifestyle measures); dose-interrupt then reduce for medically uncontrolled BP, and hold for severe/refractory hypertension. Isolated creatinine rise usually warrants monitoring and a cystatin C check; evaluate for true AKI if progressive or accompanied by proteinuria/active sediment.Lesion-level management framework

Risk factors

Pre-existing hypertension
Cardiovascular disease
Concurrent nephrotoxins or QT-prolonging drugs

Prevention

Optimize antihypertensives before/during therapy

Anticancer mechanism· how it treats cancer

Highly selective RET kinase inhibitor active against RET fusions and activating mutations; approved for RET fusion-positive NSCLC and thyroid cancers and RET-mutant medullary thyroid cancer.

§04

Clinical depth

Renal dose adjustment

Per label, no dosage modification is recommended across mild to severe renal impairment (eGFR 15-89 mL/min/1.73 m2, MDRD); the recommended dosage has not been established in end-stage renal disease, and dialysis is not studied. Weight-based dosing; modifications are driven by hypertension, QTc, hepatotoxicity, and hemorrhage.

Dialyzability & ESKD dosing

Highly protein-bound oral small molecule; not expected to be appreciably dialyzed. No validated ESKD dosing.

Differential diagnosis

Drug-induced hypertension vs essential/secondary causes; transporter-mediated pseudo-AKI (stable cystatin C, bland urine) vs true AKI (prerenal from poorly controlled BP, ATN, or AIN). A flat cystatin C with a creatinine bump indicates the transporter effect.

Monitoring

Blood pressure at baseline, after 1 week, at least monthly, and as clinically indicated
Serum creatinine periodically; cystatin C-based eGFR if a true GFR change is suspected
ECG/QTc and liver enzymes per label

Key trials & series

LIBRETTO-001 (RET fusion-positive NSCLC and thyroid; RET-mutant MTC)
LIBRETTO-431 (first-line RET fusion-positive NSCLC)
Hamidi 2024 hereditary-MTC RET-inhibitor safety series

Clinical pearls

Treat the blood pressure and check a cystatin C before assuming the creatinine rise means true GFR loss.
Hypertension is the principal renal-relevant signal — manage it to keep patients on effective RET-directed therapy.
Co-monitor QTc, since selective RET inhibitors prolong it and several antihypertensive/antiemetic co-medications also do.
A biopsy-worked-up, dose-responsive nephropathy with nephrotic features is attributed to selpercatinib — separate from its transporter-mediated creatinine artifact.
Two independent reports attribute dysnatremia to selpercatinib: SIADH improving on discontinuation (with successful reduced-dose resumption) and tubular damage with symptomatic hyponatremia and polyuria.

§05

References

8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

8 references · 2020–2025 · 4 since 2023

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 3

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseB · ModerateSelpercatinib-Associated Nephropathy in RET Fusion-Positive Lung Cancer: A Case Successfully Managed With Dose Adjustment and Nephroprotective Therapy.Oe K et al. · Clin Lung Cancer 2026 · PMID 41512743Biopsy-proven selpercatinib-associated nephropathy with nephrotic syndrome in a RET fusion-positive lung cancer patient, managed by dose reduction and nephroprotective therapy.CaseC · LimitedSelpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report.Betsema L et al. · Cancer Chemother Pharmacol 2026 · PMID 41484433Selpercatinib-induced renal tubular injury causing renal electrolyte wasting (severe hyponatremia, hypomagnesemia, hypocalcemia) and polyuria, resolving on interruption and TDM-guided rechallenge.CaseC · LimitedTumor Lysis Syndrome Induced by Selpercatinib in Rearranged During Transfection (RET) Fusion-Positive Non-Small-Cell Lung Cancer.Sagawa S et al. · Cureus 2025 · PMID 41477385Selpercatinib-induced tumor lysis syndrome with acute kidney injury (creatinine rise to 2.15 mg/dL, hyperuricemia, hyperphosphatemia) in RET fusion-positive NSCLC.

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Selpercatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Pralsetinib

Gavreto · RET inhibitor

Profile

Hypertension; rare AKI.

HTNPREPSEUDO

Mild#1 · 75% phenotype match

Brigatinib

Alunbrig · ALK TKI

Profile

Creatinine elevation; usually benign.

PSEUDOPREHTN

Mild#2 · 64% phenotype match

Lorlatinib

Lorbrena · ALK TKI

Profile

Edema and metabolic effects.

PSEUDOPREGLOM

Mild#3 · 64% phenotype match

Momelotinib

Ojjaara · JAK/ACVR1 inhibitor

Profile

2023 myelofibrosis JAK inhibitor.

PSEUDOPRE

Mild#4 · 63% phenotype match

Vimseltinib

Romvimza · CSF1R tyrosine kinase inhibitor

Profile

A clean-kidney targeted TKI — watch the CPK, not the nephron.

PSEUDOPRE

Mild#5 · 62% phenotype match

Adagrasib

Krazati · KRAS G12C inhibitor

Profile

Creatinine rise; emerging data.

PREGLOMPSEUDO

Mild#6 · 57% phenotype match

Compare Selpercatinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Other kinase inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.